

ESP/QuIP Lung EQA Scheme “Lung Cancer Related Markers” 2023

Open registration for subscheme “ESP/QuIP Lung Cancer Related Markers - Fusions: *ALK*, *ROS1*, *RET* and *MET* exon 14 skipping (molecular pathology)”

We are pleased to announce the registration for the subscheme “ESP/QuIP Lung Cancer Related Markers - Fusions: *ALK*, *ROS1*, *RET* and *MET* exon 14 skipping (molecular pathology)” 2023. The program is organized again as a cooperation between the European Society of Pathology (ESP) Foundation and QuIP (Quality in Pathology).

The information on the proficiency test is listed in the table below. Please register early to secure your spot!

Subscheme	Price	Number of participants	Registration Period	Test Period
Fusions (molecular pathology): <i>ALK</i> , <i>ROS1</i> , <i>RET</i> , <i>MET</i> exon 14 skipping	800 €	50	21.08 – 31.08.2023	23.10 – 03.11.2023

The proficiency test includes the testing of the following four markers *ALK*, *ROS1*, *RET* and *MET* exon 14 skipping. Considering that some markers are not established or relevant in all European countries, you have the possibility to unsubscribe individual markers during registering. Please click [here](#) to register. Please note that a QuIP user account is required for the registration (see [QuIP-FAQ](#)). Detailed information about sample evaluation and material can be found in the instructions for the proficiency test on our website from the start of registration.

All updates to the ESP/QuIP Lung EQA Scheme „Lung Cancer Related Markers“ 2023 program and registration will be announced on the homepages/newsletters of both [ESP](#) and [QuIP](#). For more information, please contact QuIP via office@quip.eu or +49 30 921 0717 – 0.

The proficiency test “ESP/QuIP Lung Cancer Related Markers - Fusions: *ALK*, *ROS1*, *RET* and *MET* exon 14 skipping (molecular pathology)” is kindly supported by Bristol-Myers Squibb GmbH & Co. KGaA and other sponsors in negotiation.